Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?

Oliver Ristow; Carlos Gerngroß; Markus Schwaiger; Bettina Hohlweg-Majert; Melanie Ristow; Steffen Koerdt; Roswitha Schuster; Sven Otto; Christoph Pautke

doi:10.1007/s00432-014-1588-4

journal article Jan 28, 2014

Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?

Oliver Ristow

Carlos Gerngroß Markus Schwaiger Bettina Hohlweg-Majert Melanie Ristow Steffen Koerdt Roswitha Schuster Sven Otto

Christoph Pautke

Journal of Cancer Research and Clinical Oncology Vol. 140 No. 3 pp. 487-493 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/s00432-014-1588-4

Topics

No keywords indexed for this article. Browse by subject →

References

30

[1]

Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, Russo PA, Kreusch T (2008) “Bis-phossy jaws”—high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36(2):95–103. doi: 10.1016/j.jcms.2007.06.008 10.1016/j.jcms.2007.06.008

[2]

Ackerman L, Shirazi P (1997) Abnormal skull uptake on bone scan. Semin Nucl Med 27(2):190–193 10.1016/s0001-2998(97)80049-9

[3]

Aghaloo TL, Felsenfeld AL, Tetradis S (2010) Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 68(5):959–963. doi: 10.1016/j.joms.2009.10.010 10.1016/j.joms.2009.10.010

[4]

Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suarez MA, Aguiar Morales J (2007) Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol 18(3):556–560. doi: 10.1093/annonc/mdl408 10.1093/annonc/mdl408

[5]

Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl):61–70. doi: 10.1016/j.joms.2009.01.007 10.1016/j.joms.2009.01.007

[6]

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580–8587. doi: 10.1200/JCO.2005.02.8670 10.1200/jco.2005.02.8670

[7]

Bauss F, Pfister T, Papapoulos S (2008) Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat. J Bone Miner Metab 26(4):406–408. doi: 10.1007/s00774-007-0837-x 10.1007/s00774-007-0837-x

[8]

Osteoclast differentiation and activation

William J. Boyle, W. Scott Simonet, David L. Lacey

Nature 2003 10.1038/nature01658

[9]

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31(5):578–583 10.1053/hp.2000.6698

[10]

Garetto LP, Tricker ND (1998) Remodeling of bone surrounding the implant interface. In: Garetto LP, Turner CH, Duncan RL, Burr DB (eds) Bridging the gap between dental and orthopaedic implants. Indianapolis, IN

[11]

Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Min Res 12(4):498–508. doi: 10.1359/jbmr.1997.12.4.498 10.1359/jbmr.1997.12.4.498

[12]

Hansen PJ, Knitschke M, Draenert FG, Irle S, Neff A (2012) Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment-a grossly underestimated risk? Clin Oral Invest. doi: 10.1007/s00784-012-0873-3

[13]

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F (2008) EAU guidelines on prostate cancer. Eur Urol 53(1):68–80. doi: 10.1016/j.eururo.2007.09.002 10.1016/j.eururo.2007.09.002

[14]

Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Mineral Res 23(6):826–836. doi: 10.1359/jbmr.080205 10.1359/jbmr.080205

[15]

Huja SS, Fernandez SA, Hill KJ, Li Y (2006) Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 288(12):1243–1249. doi: 10.1002/ar.a.20396 10.1002/ar.a.20396

[16]

Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, Haus U, Stephan C, Meissner S, Loening SA, Jung K (2007) Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. Eur Urol 52(5):1381–1387. doi: 10.1016/j.eururo.2007.02.033 10.1016/j.eururo.2007.02.033

[17]

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

Robert E Marx

Journal of Oral and Maxillofacial Surgery 2003 10.1016/s0278-2391(03)00720-1

[18]

Morris PG, Poznak CV, Modi S, Mak AF, Patil S, Larson S, Hudis CA, Divgi C, Grewal RK (2010) Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. Clin Breast Cancer 10(1):33–39. doi: 10.3816/CBC.2010.n.004 10.3816/cbc.2010.n.004

[19]

Otto S, Hafner S, Grotz KA (2009) The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67(3):589–592. doi: 10.1016/j.joms.2008.09.028 10.1016/j.joms.2008.09.028

[20]

Otto S, Hafner S, Mast G, Tischer T, Volkmer E, Schieker M, Sturzenbaum SR, von Tresckow E, Kolk A, Ehrenfeld M, Pautke C (2010) Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg 68(5):1158–1161. doi: 10.1016/j.joms.2009.07.079 10.1016/j.joms.2009.07.079

[21]

Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Sturzenbaum S, Pautke C (2012) Bisphosphonate-related osteonecrosis of the jaws—characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40(4):303–309. doi: 10.1016/j.jcms.2011.05.003 10.1016/j.jcms.2011.05.003

[22]

Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone 44(1):4–10. doi: 10.1016/j.bone.2008.09.012 10.1016/j.bone.2008.09.012

[23]

Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41(3):318–320. doi: 10.1016/j.bone.2007.04.196 10.1016/j.bone.2007.04.196

[24]

Ristow O, Gerngroß C, Schwaiger M, Hohlweg-Majert B, Kehl V, Jansen H, Hahnefeld L, Otto S, Pautke C (2013) Is the bone turnover of the jawbone and its possible oversuppression by bisphosphonates of etiological importance for the pathogenesis of the bisphosphonate-related osteonecrosis? J Oral Maxillofac Surg. doi: 10.1016/j.joms.2013.11.005 10.1016/j.joms.2013.11.005

[25]

Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AM, Ribatti D, Dammacco F, Vacca A (2007) Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 6(12 Pt 1):3256–3262. doi: 10.1158/1535-7163.MCT-07-0311 10.1158/1535-7163.mct-07-0311

[26]

Then C, Horauf N, Otto S, Pautke C, von Tresckow E, Rohnisch T, Baumann P, Schmidmaier R, Bumeder I, Oduncu FS (2012) Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Onkologie 35(11):658–664. doi: 10.1159/000343950 10.1159/000343950

[27]

Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB (2010) Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid. Oral Oncol 46(3):214–218. doi: 10.1016/j.oraloncology.2010.01.001 10.1016/j.oraloncology.2010.01.001

[28]

Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54(5):1066–1072. doi: 10.1016/j.eururo.2008.06.070 10.1016/j.eururo.2008.06.070

[29]

Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Invest 14(1):35–41. doi: 10.1007/s00784-009-0266-4 10.1007/s00784-009-0266-4

[30]

Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D (2006) The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 91(9):1165–1171

Metrics

15

Citations

30

References

Details

Published: Jan 28, 2014
Vol/Issue: 140(3)
Pages: 487-493
License: View

Authors

O

Oliver Ristow

Department of Oral and Maxillofacial Surgery, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany

Bettina Hohlweg-Majert

Cite This Article

Oliver Ristow, Carlos Gerngroß, Markus Schwaiger, et al. (2014). Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?. Journal of Cancer Research and Clinical Oncology, 140(3), 487-493. https://doi.org/10.1007/s00432-014-1588-4

Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?

You May Also Like